期刊文献+

BSD2000相控阵聚焦热疗联合化疗治疗耐药性卵巢上皮癌患者恶性腹腔积液的效果

Effect of BSD 2000 deep thermotherapy plus chemotherapy in treatment of malignant seroperitoneum of advanced epithelial ovarian cancer patients with drug resistance
原文传递
导出
摘要 目的 观察BSD 2000相控阵聚焦热疗联合化疗对耐药性卵巢上皮癌患者恶性腹腔积液的疗效.方法 36例耐药性卵巢上皮癌恶性腹腔积液患者按抽签法随机分为治疗组和对照组各18例,其中治疗组采用BSD 2000相控阵聚焦热疗+GT方案(吉西他滨1 000 mg/m2静脉滴注,第1、8天;紫杉醇80 mg/m2腹腔注射,第1、8天)化疗;对照组单独采用GT方案化疗.28 d为1个周期,2个周期后评价疗效、患者不良反应、Karnofsky评分、中位生存时间.结果 治疗组有效率(RR)高于对照组[55.6%(10/18)比22.2%(4/18),P<0.05],疾病控制率(DCR)亦高于对照组,但差异无统计学意义(P>0.05).两组不良反应类似,无Ⅲ~Ⅳ度不良反应发生.治疗组Karnofsky评分改善率高于对照组,差异无统计学意义(P>0.05).两组患者中位生存时间、生存率比较差异均无统计学意义(均P> 0.05).结论 BSD 2000相控阵聚焦热疗联合化疗可有效控制耐药性卵巢上皮癌患者恶性腹腔积液,改善患者生命质量,不良反应轻微. Objective To observe the effect of BSD 2000 deep thermotherapy plus chemotherapy in treatment of malignant seroperitoneum of advanced epithelial ovarian cancer patients with drug resistance.Methods 36 advanced epithelial ovarian cancer patients with malignant seroperitoneum for drug resistance were randomly divided into two groups,trial group (18 cases) and control group (18 cases).Cases in trial group were treated with BSD 2000 deep thermotherapy plus GT regimen (gemcitabine 1 000 mg/m2 iv d1,d8,taxinol 80 mg/m2 ip d1,d8.28 days for a cycle),while control group with GT regimen alone.Effect,survival time (median) toxicity and Karnofsky score were evaluated after 2 cycles.Results Response rate (RR) was strongly higher in trial group compared with control group [55.6 % (10/18) vs 22.2 % (4/18),P 〈 0.05],the same to disease control rate (DCR),but there was not significant difference between two groups (P 〉 0.05).The improvement rate of Karnofsky score in trial group was higher than that in control group,which had no significance (P 〉 0.05).The toxicity were similar in both groups,which had no stage 3 to 4 side-effect.The differences of survival time (median) and survival rate had no statistical significance between two groups (P 〉 0.05).Conclusion It is useful to eliminate seroperitoneum,improve quality of life and decrease the toxicity for the regimen of BSD 2000 deep thermotherapy plus chemotherapy in treatment of malignant seroperitoneum of advanced epithelial ovarian cancer patients with drug resistance.
出处 《肿瘤研究与临床》 CAS 2015年第6期409-412,共4页 Cancer Research and Clinic
关键词 卵巢肿瘤 高温 诱发 药物疗法 腹腔积液 恶性 抗药性 肿瘤 Ovarian neoplasms Hyperthermia,induction Drug therapy Seroperitoneum,malignant Drug resistance,neoplasm
  • 相关文献

参考文献11

  • 1Fleming GF, Ronnett BM, Seidman J. Epithelial ovarian cancer// Barakat RR, Markman M, Randall ME, et al. Principles and practice of gynecologic oncology[M]. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2009: 763-836. 被引量:1
  • 2Chan JK, Cheung MK, Husain A, et al. Patterns and progress in ovarian cancer over 14 years[J]. Obstet Gynecol, 2006, 108(3 Pt 1): 521-528. 被引量:1
  • 3刘纯一.体外高频热疗在不同时机对恶性胸腹腔积液治疗的疗效观察[J].河北医药,2009,31(21):2928-2929. 被引量:13
  • 4Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin[J]. J Clin Oncol, 1991, 9(3): 389-393. 被引量:1
  • 5Markman M, Blessing J, Rubin SC, et al. Phase Ⅱ trial weekly paclitaxel (80 mg/m2)in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2006, 101(3): 436-440. 被引量:1
  • 6Sharma R, Graham J, Mitchell H, et al. Extended weekly dosedense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer[J]. Br J Cancer, 2009, 100(5): 707-712. 被引量:1
  • 7Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J]. N Engl J Med, 2006, 354(1): 34-43. 被引量:1
  • 8Stein U, Jurchott K, Walther W, et al. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters[J]. J Biol Chem, 2003, 276(30): 28562-28569. 被引量:1
  • 9Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer:a phase 3, open-label, randomised controlled trial[J].Lancet, 2009, 374 (9698): 1331-1338. 被引量:1
  • 10魏泽雄,王晓凤,胡丹,葛四平,罗鸣.腹腔灌注化疗联合局部高频热疗治疗恶性腹水的临床分析[J].现代肿瘤医学,2009,17(6):1113-1114. 被引量:7

二级参考文献18

  • 1孙静,胜照杰,王俊生,牛春莲.腹腔热化疗治疗恶性腹水的临床观察[J].河南肿瘤学杂志,2004,17(4):245-247. 被引量:7
  • 2王娟,陈峻青.卡铂腹腔化疗药代动力学实验研究[J].中华肿瘤杂志,1994,16(3):196-198. 被引量:92
  • 3Kitamura K,Saeki H,Kawaguchi H,el al.Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied speimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer[J].Hepatogastroenterology,2000,47(32):419-423. 被引量:1
  • 4Wei YQ, Zhao X, Kariya Y, et al. Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of γ δ cells and heat shock protein 70[J]. Cancer Res, 1996,56(5):1104-1110. 被引量:1
  • 5Okamoto M, Tazawa K, Kawagoshi T, et al. The combined effect against colon-26 cells of heat treatment and immunization with heat treated colon-26 tumor cell extract[J]. Int J Hyperthermia, 2000, 16(3) :263-273. 被引量:1
  • 6Multhoff G. Heat Shock protein 72 (Hsp72), a hyperthennia-inducible imrmmogenic determinant on leukemic K562 and Ewing's sarcoma cells[J]. Int J Hyperthennia, 1997,13(1):39-48. 被引量:1
  • 7Multhoff G, Botzler C, Wiesnet M, et al. A stress-inducible 72 kD heat-shcek protein is enpressed the surface of human tumor cells, but not on normal cells[J]. Int J Cancer, 1995,61(2) :272-279. 被引量:1
  • 8Ito A, Shinkai M, Honda H, et al. Heat shock protein 70 express induce antitumor immunity during intracellular hyperthermia using magnetite nanoparticles[J]. Cancer Immunol Immunother, 2003,52(2):80-88. 被引量:1
  • 9Ito A, Matsuoka F, Honda H, et al. Heat shock proten 70 gene therapy combined with hyperthermia using magnetite nanoparticles [J].Cancer Gene Therapy, 2003, 10(12) : 918-925. 被引量:1
  • 10Ito A, Matsuoka F, Honda H, et al, Antitumor effects of combined therapy of recombinant heat shcek protein 70 and hyperthennia using magnetite nanopartides, in an experimental subcutaneous routine melanoma[J]. Cancer Immunol Immunother, 2004,53 ( 1 ) : 20-32. 被引量:1

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部